Showing 1,570 results

Filters Content type: News, Editors' picks, About HIV Topic: Pharmaceutical industry

News and information on drug companies, the cost of therapies, patent protections and generic medicines.

Pharmaceutical industry

Oil price shocks could raise the cost of HIV medicines by up to 44%, Unitaid analysis finds

Editor's pick
Unitaid
27 July 2026
Access to healthcare

Activists React to Merck’s Voluntary License for Generic Production of Investigational Long-Acting Oral PrEP Product, Alimatravir

Editor's pick
Health GAP (Global Access Project)
27 July 2026
Access to healthcare

With Hopes High for New H.I.V. Prevention Pill, Merck Takes Steps to Ensure Access

Editor's pick
The New York Times (requires free registration)
26 July 2026
HIV treatment for children & young people

ViiV Healthcare advances paediatric HIV regulatory submissions with FDA  Priority  Review for Tivicay PD and  EMA  validation  of marketing application  for  Tivicay 

Editor's pick
ViiV Healthcare press release
22 June 2026
Injectable & long-acting PrEP

Gilead cranks up Yeztugo first-year sales forecast to $1B on 'unprecedented launch trajectory'

Editor's pick
FiercePharma
11 May 2026
Pharmaceutical industry

Seeking justice for 24,000 people living with HIV before the California Supreme Court

Editor's pick
Positively Aware
7 May 2026
PrEP science

Scientists develop a cheaper and more sustainable way to manufacture breakthrough HIV drug Lenacapavir

Editor's pick
University of Manchester
13 April 2026
New & experimental HIV treatments

Gilead cancels midstage HIV trial as FDA’s clinical hold remains intact

Editor's pick
FierceBiotech
2 April 2026
Injectable & long-acting PrEP

Gilead refuses to sell groundbreaking HIV prevention drug to MSF

Editor's pick
Médecins Sans Frontières
31 March 2026
Injectable & long-acting PrEP

Solving the PrEP Access Problem, One Subscription at a Time

Editor's pick
TheBodyPro
30 March 2026
Access to healthcare

Civil Society Demands Access Strategy for Merck’s Promising Long-Acting HIV Prevention Pill Covering all Low- and Middle-Income Countries

Editor's pick
Health GAP (Global Access Project)
12 February 2026
Pharmaceutical industry

Pfizer sells its stake in GSK's ViiV for $1.9B, with Shionogi upping its ante in the HIV-focused company

Editor's pick
FiercePharma
26 January 2026
Access to healthcare

US: PrEP Users Applaud CVS and Gilead Agreement on Yeztugo

Editor's pick
PrEP4All
15 January 2026
Pharmaceutical industry

Details Matter When Casting People Living with HIV

Editor's pick
My Fabulous Disease
15 January 2026
PrEP policies & guidelines

South Africa wants to make its own six-monthly HIV prevention jabs by 2027. But there’s a hitch

Editor's pick
Bhekisisa
8 December 2025
Access to healthcare

The 2025 HIV Market Report: The state of the HIV market in low- and middle-income countries

Editor's pick
Clinton Health Access Initiative
26 November 2025
New & experimental HIV treatments

Gilead hails phase 3 victory for single-tablet combo of bictegravir and lenacapavir, preps filings

Editor's pick
FiercePharma
17 November 2025
Injectable & long-acting HIV treatment

Gilead ends phase 1 trial after settling on twice-yearly treatment partner for lenacapavir

Editor's pick
FierceBiotech
3 November 2025
Injectable & long-acting PrEP

Gilead's long-acting PrEP Yeztugo takes off while cell therapy declines continue to haunt sales

Editor's pick
FiercePharma
3 November 2025
Injectable & long-acting PrEP

South African firms lose out on lenacapavir production

Editor's pick
Juta MedicalBrief
23 October 2025
Pharmaceutical industry

HIV Preventive Treatment Could Be Sold for One Thousandth of Current List Price

Editor's pick
Infectious Disease Society of America
21 October 2025
Pharmaceutical industry

Gilead inks trio of Biktarvy patent settlements, waylaying US copycats until 2036

Editor's pick
FiercePharma
9 October 2025
PrEP policies & guidelines

Joint Statement: Activists Demand $40-a-Year Generic Price for Breakthrough HIV Prevention Drug Be Made Available to All Low- and Middle Income Countries

Editor's pick
Treatment Action Group
25 September 2025
Pharmaceutical industry

Lenacapavir in South Africa: There are mounting concerns over transparency in cost

Editor's pick
Health-E News
15 September 2025